STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma

NCT ID: NCT00252824

Last Updated: 2011-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Symbicort

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Diagnosis of asthma ³ 3 months
* Prescribed daily use of glucocorticosteroids at a dose \> 320 mcg/ day for at least 3 months prior to Visit 1

Exclusion Criteria

* Smoking history \> 10 pack-years
* Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
* Any significant disease or disorder that my jeopardize the safety of the patient.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca Symbicort Medical Science Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Quillota, , Chile

Site Status

Research Site

Valparaíso, , Chile

Site Status

Researh Site

Dubrovnik, , Croatia

Site Status

Research Site

Split, , Croatia

Site Status

Research Site

Zagreb, , Croatia

Site Status

Research Site

Brno, , Czechia

Site Status

Research Site

Hradec Králové, , Czechia

Site Status

Research Site

Jihlava, , Czechia

Site Status

Research Site

Litomice, , Czechia

Site Status

Research Site

Ostrava, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prostijov, , Czechia

Site Status

Research Site

Strakonice, , Czechia

Site Status

Research Site

Ahens, , Greece

Site Status

Research Site

Alexandroup, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Kavala, , Greece

Site Status

Research Site

Akureyri, , Iceland

Site Status

Research Site

Reykjavik, , Iceland

Site Status

Research Site

Daugavpils, , Latvia

Site Status

Research Site

Riga, , Latvia

Site Status

Research Site

Rigas Raj, , Latvia

Site Status

Research Site

Kaunas, , Lithuania

Site Status

Research Site

Klaipėda, , Lithuania

Site Status

Research Site

Vilnius, , Lithuania

Site Status

Research Site

Aveiro, , Portugal

Site Status

Research Site

Coimbra, , Portugal

Site Status

Research Site

Coviha, , Portugal

Site Status

Research Site

Lisbon, , Portugal

Site Status

Research Site

Porto, , Portugal

Site Status

Research Site

Setúbal, , Portugal

Site Status

Research Site

Vila Nova de Gaia, , Portugal

Site Status

Research Site

Banská Bystrica, , Slovakia

Site Status

Research Site

Bardejov, , Slovakia

Site Status

Research Site

Bratislava, , Slovakia

Site Status

Research Site

Hlohovec, , Slovakia

Site Status

Research Site

Košice, , Slovakia

Site Status

Research Site

Liptovský Hrádok, , Slovakia

Site Status

Research Site

Malacky, , Slovakia

Site Status

Research Site

Nitra Zobor, , Slovakia

Site Status

Research Site

Partizánske, , Slovakia

Site Status

Research Site

Revúca, , Slovakia

Site Status

Research Site

Senec, , Slovakia

Site Status

Research Site

Topostany, , Slovakia

Site Status

Research Site

Žilina, , Slovakia

Site Status

Research Site

Celje, , Slovenia

Site Status

Research Site

Golnik, , Slovenia

Site Status

Research Site

Kamnik, , Slovenia

Site Status

Research Site

Koper, , Slovenia

Site Status

Research Site

Litija, , Slovenia

Site Status

Research Site

Ljubljana, , Slovenia

Site Status

Research Site

Murska Sobota, , Slovenia

Site Status

Research Site

Nova Gorica, , Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Chile Croatia Czechia Greece Iceland Latvia Lithuania Portugal Slovakia Slovenia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STYLE

Identifier Type: -

Identifier Source: secondary_id

D5890L00014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.